Eli Lilly completes acquisition of EtaiBexli, adding treatment-resistant depression programs
On 2026-09-20 WISH-TV reported that Indianapolis-based Eli Lilly announced the completion of its acquisition of biopharmaceutical company EtaiBexli, which is developing treatments for mental health conditions including treatment-resistant depression.
On 2026-09-20, WISH-TV reported that Indianapolis-based Eli Lilly announced completion of its acquisition of biopharmaceutical company EtaiBexli. EtaiBexli is described as developing treatments for mental health conditions, including treatment-resistant depression.
Report a correction · Editorial standards · Our source directory
BusinessIndy examines this development and its implications for Indiana businesses and communities using the linked sources.
Continued verification is in progress.
Sources
Source date recorded as September 20, 2026 at 2:15 PM EDT. A sourced news brief; no independent staff reporting is implied. Prepared with AI assistance; source-dependent claims remain attributed in the article.
Reader discussion
Join the discussion. Every comment is checked before publication. Community rules and appeals